Article
Oncology
Fabian Falkenbach, Francesca Ambrosini, Pierre Tennstedt, Matthias Eiber, Matthias M. Heck, Felix Preisser, Markus Graefen, Lars Budaeus, Daniel Koehler, Sophie Knipper, Tobias Maurer
Summary: This study found that both BCR risk groups and PSA kinetics are not predictive factors for the success of PSMA-RGS performed at low absolute PSA values. Additionally, indolent low-risk BCR is rarely treated with PSMA-RGS.
Article
Oncology
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stephane Oudard
Summary: This study analyzed a phase III trial dataset in metastatic prostate cancer patients, demonstrating the significant prognostic value of modeled PSA kinetics parameters assessed using mathematical modeling. The results suggest that these parameters could serve as early prognostic/predictive factors in patients undergoing systemic treatments.
Article
Endocrinology & Metabolism
Emerson E. Lee, Tanmay Singh, Chen Hu, Misop Han, Curtiland Deville, Aditya Halthore, Stephen Greco, Phuoc Tran, Theodore DeWeese, Daniel Y. Song
Summary: This study found that initiating salvage radiation therapy (SRT) when PSA levels are below 0.5 ng/ml is associated with improved metastasis-free survival (MFS) in patients with biochemical recurrence. Seminal vesicle invasion is also associated with shorter time to biochemical failure and eventual metastasis.
Article
Oncology
Ken Chow, Justin Bedo, Andrew Ryan, Dinesh Agarwal, Damien Bolton, Yee Chan, Philip Dundee, Mark Frydenberg, Marc A. Furrer, Jeremy Goad, Dennis Gyomber, Uri Hanegbi, Laurence Harewood, Dennis King, Alastair D. Lamb, Nathan Lawrentschuk, Peter Liodakis, Daniel Moon, Declan G. Murphy, Justin S. Peters, Paul Ruljancich, Clare L. Verrill, David Webb, Lih-Ming Wong, Homayoun Zargar, Anthony J. Costello, Anthony T. Papenfuss, Christopher M. Hovens, Niall M. Corcoran
Summary: Ductal adenocarcinoma, an uncommon variant of prostate cancer, is associated with worse clinical outcomes. Patients with ductal variant histology demonstrated shorter salvage-free survival and metastasis-free survival. RB1 loss and copy number gains in TAP1, SLC4A2, and EHHADH were consistently associated with ductal variant histology.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Cheng-Yu Huang, Chung-Hsin Chen
Summary: The study aimed to investigate the clinical presentation and survival outcomes of patients with both a high PSA value and non-metastatic prostate cancer. The results showed that patients with non-metastatic prostate cancer and high PSA levels obtained survival benefits from local prostate-definitive treatments.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, Research & Experimental
Ran Zhang, Feng Liu
Summary: This study established CAF gene signatures that accurately predict the prognosis of prostate cancer patients undergoing radiotherapy.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
D. Das, S. Basu, N. Rana, S. Roy, B. Hazra, K. Sen
Summary: This study presents a hassle-free, rapid, and green synthesis method for a novel fluorosensor CuI@graphene nano-composite (CuI@Gr) for antibody-free optical sensing of prostate-specific antigen (PSA), a biomarker for prostate cancer. The CuI@Gr nanoparticles showed enhanced efficacy in detecting PSA in serum medium with a ten-fold lower limit of detection (0.331 pg/mL) compared to CuI nanoparticles. Moreover, the CuI@Gr nanoparticles demonstrated improved detection efficiency even in the presence of interfering biomolecules such as glucose and cholesterol, commonly found in serum due to comorbidities.
MATERIALS TODAY CHEMISTRY
(2022)
Article
Oncology
Frank C. Cackowski, Elisabeth I. Heath
Summary: Prostate cancer has the unique ability to lie dormant and recur long after treatment, with important reservoirs for dormant tumor cells in the bone marrow, lymph nodes, and the prostate bed. The induction of cellular dormancy in prostate cancer cells involves complex signaling pathways and interactions with the microenvironment, and current adjuvant therapies are only modestly successful in preventing recurrence, indicating the need for further advancements in systemic adjuvant therapy.
Article
Urology & Nephrology
Martin Boegemann, Neal D. Shore, Matthew R. Smith, Teuvo L. J. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi
Summary: The study evaluated the efficacy and safety of darolutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer. It found that darolutamide significantly prolonged metastasis-free survival, improved overall survival, and did not cause many side effects.
Article
Multidisciplinary Sciences
Ogul E. Uner, Thonnie Rose O. See, Eszter Szalai, Hans E. Grossniklaus, Gustav Stalhammar
Summary: The study found that BAP1 mutations in uveal melanoma occur early in tumor growth, typically appearing in the initial stages, and coincide with the seeding of micrometastases.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Volkan Sabur, Ibrahim Untan, Atila Tatlisen
Summary: The study demonstrated that PSADT, PSAV, and nadir PSA are independent prognostic markers for survival in patients with HRPCa, helping clinicians predict survival in these patients.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Article
Oncology
Aradhana M. Venkatesan, Eniola Mudairu-Dawodu, Cihan Duran, R. Jason Stafford, Yuanqing Yan, Wei Wei, Vikas Kundra
Summary: The study found that the utility of mpMRI in detecting suspected local recurrence post RP is associated with PSA and Gleason grade. In patients with lower Gleason grade and low PSA, mpMRI results are likely to be negative; while in patients with higher Gleason grade and high PSA, mpMRI results are likely to be positive. This can help guide further diagnostic and treatment decisions in patients with suspected recurrence.
Article
Urology & Nephrology
Jean F. P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, Rafael F. Coelho, Jose Jr Jr Pontes, Diogo A. Bastos, Mauricio D. Cordeiro, Alvaro S. Sarkis, Sheila F. Faraj, Anuar Mitre, Miguel Srougi, William C. Nahas
Summary: This study aimed to compare the effects of extended pelvic lymph node dissection and limited lymph node dissection in the surgical management of prostate cancer patients, and did not demonstrate a significant advantage of EPLND in reducing biochemical recurrence.
Article
Multidisciplinary Sciences
Ming Yang, Xudong Zhu, Yang Shen, Qi He, Yuan Qin, Yiqun Shao, Lin Yuan, Hesong Ye
Summary: This study successfully established a prognostic model for prostate cancer recurrence-free survival and identified the biomarker GPX2. It revealed that GPX2 regulates the progression of prostate cancer and triggers molecular changes in the Wnt/β-catenin/EMT pathway.
Article
Cell Biology
Jing Chen, Jialin Meng, Yi Liu, Zichen Bian, Qingsong Niu, Junyi Chen, Jun Zhou, Li Zhang, Meng Zhang, Chaozhao Liang
Summary: This study developed a classifier based on Enzalutamide treatment resistance-related genes to predict the recurrence-free survival (RFS) prognosis of prostate cancer patients after radical prostatectomy. The classifier showed good predictive values and independent prognostic ability. Combining the classifier with clinicopathological factors improved the predictive accuracy. Differences between high- and low-risk subgroups were enriched in cancer progression-related pathways.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Review
Endocrinology & Metabolism
Samuel Denmeade, Emmanuel S. Antonarakis, Mark C. Markowski
Summary: Bipolar androgen therapy (BAT) is a new treatment concept that can be safely administered to asymptomatic patients with metastatic castrate-resistant prostate cancer. BAT produces sustained prostate-specific antigen and objective responses in 30%-40% of patients and can resensitize and prolong response to subsequent antiandrogen therapy.
Article
Endocrinology & Metabolism
Emmanuel S. Antonarakis, Marni Tierno, Virginia Fisher, Hanna Tukachinsky, Sonja Alexander, Omar Hamdani, Matthew C. Hiemenz, Richard S. P. Huang, Geoffrey R. Oxnard, Ryon P. Graf
Summary: Liquid biopsy is a powerful tool for guiding treatment decisions for metastatic prostate cancer patients with difficult-to-biopsy tumors, yet its efficacy is limited by the tumor fraction of circulating tumor DNA. This study validated and provided additional resolution for clinicians to anticipate the probability of successful liquid biopsy profiling based on commonly assessed clinical and laboratory features. Results showed that PSA levels, blood markers, and timing of liquid biopsy collection were strongly associated with the tumor fraction in liquid biopsy samples.
Editorial Material
Endocrinology & Metabolism
Emmanuel S. Antonarakis
Editorial Material
Urology & Nephrology
Editorial Eugene Shenderov, Emmanuel S. Antonarakis
Article
Endocrinology & Metabolism
Christopher T. Su, Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul R. Aggarwal, Rana R. McKay, Neeraj Agarwal, Heather M. McClure, Nellie Nafissi, Alan H. Bryce, Oliver Sartor, Nicolas Sayegh, Heather H. Cheng, Nabil Adra, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Ajjai S. Alva, Emmanuel S. Antonarakis
Summary: PARP inhibitors (PARPi) are standard treatment for mCRPC patients with specific mutations, but response may differ in patients with ATM and BRCA2 mutations. We investigated differences in response to taxanes, which may inform treatment sequencing decisions.
Article
Oncology
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Summary: PSMA-targeted radioligand therapy has significantly improved clinical outcomes in men with mCRPC. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Summary: The purpose of this study was to investigate the impact of sequential or concurrent administration of androgen receptor-targeting agents (ARTAs) on sipuleucel-T immune response and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC). The results showed that the median OS remained consistent regardless of whether the agents were administered sequentially or concurrently, and sipuleucel-T induced an immunologic prime-boost effect after initial exposure, even when combined with ARTAs.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Adel Mandl, Mark C. Markowski, Michael A. Carducci, Emmanuel S. Antonarakis
Summary: The BET family of proteins are crucial in activating oncogenic networks in different cancers. Therapeutic targeting of BET proteins has shown potential in treating metastatic castration-resistant prostate cancer. However, clinical success has been limited due to treatment-associated toxicities, drug resistance, and a lack of biomarkers.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Oncology
Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small
Summary: The purpose of this study was to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. The results showed that the addition of AAP did not provide a statistically significant benefit in OS compared to enzalutamide treatment alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Emmanuel S. Antonarakis, Wassim Abida
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Ali. T. T. Arafa, Leah. R. R. Blader, Karan Ramakrishna, Jeff Engle, Charles. J. J. Ryan, Nicholas. A. A. Zorko, Gautam Jha, Emmanuel. S. S. Antonarakis
Summary: This study evaluated the impact of androgen deprivation therapy (ADT) cessation in patients starting abiraterone for castration-resistant prostate cancer. The results showed that abiraterone alone was associated with comparable clinical outcomes to abiraterone plus ADT. Further prospective studies are needed to assess the impact of abiraterone alone on treatment outcomes and cost savings.
Review
Endocrinology & Metabolism
Ali T. T. Arafa, Aditya Jain, Pavel Skrobanek, Brad Humphrey, Jerry W. W. Froelich, Emmanuel S. S. Antonarakis
Summary: This study assessed the impact of Piflufolastat F-18 (18F-DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging on clinical practice. The results showed that this technology significantly influenced the initial staging, biochemical recurrence, and restaging of metastatic prostate cancer.
Review
Oncology
Angela Y. Y. Jia, Ana P. Kiess, Qiubai Li, Emmanuel S. Antonarakis
Summary: The discovery of small molecules targeting the extracellular domain of PSMA has advanced diagnostic imaging and precision radiopharmaceutical therapies. This review presents existing data and ongoing clinical evaluations of PSMA-based imaging in the management of prostate cancer. It also discusses clinical studies on PSMA-based radiopharmaceutical therapy and forthcoming trials on early disease states. Multidisciplinary collaboration in trial design and therapeutic administration is crucial for the continued progress of this radiotheranostics field.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Oncology
Sree M. Lanka, Nicholas A. Zorko, Emmanuel S. Antonarakis, Pedro C. Barata
Summary: The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of several genitourinary malignancies, but the utility of immunotherapies in prostate cancer has been limited due to its immunologically cold tumor terrain. Pembrolizumab is currently the only approved ICI for metastatic castration resistant prostate cancer (mCRPC) in a select group of patients. Future research is exploring combination approaches with ICIs and other treatments to enhance their efficacy in mCRPC. Additionally, alternative checkpoint inhibitors like B7-H3 hold promise in expanding the treatment options for mCRPC.